83 results
Page 2 of 5
6-K
EX-99.3
iefdy9gn1qn5
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
13orte5
18 Apr 23
Immunocore presents new KIMMTRAK data confirming association between early ctDNA reduction and longer overall survival
4:15pm
6-K
EX-99.1
yfw00xqgqbon2tg
8 Dec 22
Immunocore presents ovarian cancer expansion data for ImmTAC® candidate IMC-C103C targeting MAGE-A4
4:59pm
6-K
EX-99.1
gd0d37 8xwkr9zl
2 Dec 22
Immunocore and Gadeta Announce Agreement to Develop First Gamma Delta (γδ) TCR ImmTAC for Solid Tumors
5:08pm
6-K/A
EX-99.1
t4khl8a90det7uvo8v
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.1
yns6g876g0jo4egw
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
2ctfx33o9akkhqyc4v
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
3vs 40q59
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
di3a3x
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
wd7jrz
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
zpym4tgvu9 z8q3w
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.2
5haceszz
9 Sep 22
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at the ESMO 2022 Congress
12:33pm
6-K
EX-99.3
r2yslx
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.4
wm3av
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.1
49h37c ggpcakm81
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
6-K
EX-99.2
9sgh1fop3t2q3ljglp6
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am
D
pl7d9d
28 Jul 22
$140M in equity, sold $140M, 8 investors
4:57pm
6-K
EX-99.1
mjjoubt
6 Jun 22
Immunocore presents new data on KIMMTRAK (tebentafusp-tebn) in metastatic
4:21pm
6-K
EX-99.1
fmuwc
3 Jun 22
Sanofi will evaluate KIMMTRAK in combination with SAR444245 as part of its ongoing Phase 1 study in advanced unresectable or metastatic skin cancers
4:05pm
6-K
EX-99.3
xhctbbcw80pdxjp
11 May 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:08am